Lv1
10 积分 2026-01-21 加入
PO.6.127 Efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory t cells in patients with SLE: final results of a phase 1b multiple ascending dose study
14小时前
已完结
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
14小时前
已完结
Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin
14小时前
已完结
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
14小时前
已完结
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke
3个月前
已完结
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
4个月前
已完结
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
4个月前
已完结
LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial
4个月前
已关闭
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
5个月前
已完结
P2.01-51 Study of CD26/DPP4 Expression in a Large Series of Non-Small Cell Lung Cancer Patients
6个月前
已完结
皖公网安备34019202002308
